Stefan E. Eng

Stefan E. Eng

Auto-generated profile, based on publicly available information

Stefan E. Eng

Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
GPGundula Povysil
Gundula Povysil
JKJack A. Kosmicki
Jack A. Kosmicki
ECElizabeth T. Cirulli
Elizabeth T. Cirulli
TDTheodore Drivas
Theodore Drivas
JRJ Brent Richards
J Brent Richards
Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75–10.05, p = 5.41x10-7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.

24 March 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
XXXin Xu
Xin Xu
HZHelen Zhu
Helen Zhu
RHRupert Hugh-White
Rupert Hugh-White
JLJulie Livingstone
Julie Livingstone
SEStefan Eng
Stefan Eng
HHHousheng Hansen He
Housheng Hansen He
N6-methyladenosine (m6A), the most abundant internal RNA modification in humans, regulates most aspects of RNA processing. Prostate cancer is characterized by widespread transcriptomic dysregulation; therefore, we characterized the m6A landscape of 162 localized prostate tumors with matched DNA, RNA and protein profiling. m6A abundance varied dramatically across tumors, with global patterns emerging via complex germline–somatic cooperative regulation. Individual germline polymorphisms regulated m6A abundance, cooperating with somatic mutation of cancer driver genes and m6A regulators. The resulting complex patterns were associated with prognostic clinical features and established the biomarker potential of global and locus-specific m6A patterns. Tumor hypoxia dysregulates m6A profiles, bridging prior genomic and proteomic observations. Specific m6A sites, such as those in VCAN, drive disease aggression, associating with poor outcomes, tumor growth and metastasis. m6A dysregulation is thus associated with key events in the natural history of prostate cancer: germline risk, microenvironmental dysregulation, somatic mutation and metastasis.

28 October 2024 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
WUWhitney P. Underwood
Whitney P. Underwood
MMMeghan G. Michalski
Meghan G. Michalski
CLCatherine P. Lee
Catherine P. Lee
GFGina A. Fickera
Gina A. Fickera
SCSu S. Chun
Su S. Chun
LJLee W. Jones
Lee W. Jones
We developed and evaluated the Digital Platform for Exercise (DPEx): a decentralized, patient-centric approach designed to enhance all aspects of clinical investigation of exercise therapy. DPEx integrated provision of a treadmill with telemedicine and remote biospecimen collection permitting all study procedures to be conducted in patient’s homes. Linked health biodevices enabled high-resolution monitoring of lifestyle and physiological response. Here we describe the rationale and development of DPEx as well as feasibility evaluation in three different cohorts of patients with cancer: a phase 0a development study among three women with post-treatment primary breast cancer; a phase 0b proof-of-concept trial of neoadjuvant exercise therapy in 13 patients with untreated solid tumors; and a phase 1a level-finding trial of neoadjuvant exercise therapy in 53 men with localized prostate cancer. Collectively, our study demonstrates the utility of a fully digital, decentralized approach to conduct clinical trials of exercise therapy in a clinical population.

12 September 2022 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
SEStefan E. Eng
Stefan E. Eng
BBBenjamin Basasie
Benjamin Basasie
ALAlfonso Lam
Alfonso Lam
OSO. John Semmes
O. John Semmes
DTDean A. Troyer
Dean A. Troyer
MLMichael A. Liss
Michael A. Liss

7 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
YPYash Patel
Yash Patel
CZChenghao Zhu
Chenghao Zhu
TYTakafumi N. Yamaguchi
Takafumi N. Yamaguchi
NWNicholas K. Wang
Nicholas K. Wang
NWNicholas Wiltsie
Nicholas Wiltsie
PBPaul C. Boutros
Paul C. Boutros
Summary DNA sequencing is becoming more affordable and faster through advances in high-throughput technologies. This rise in data availability has contributed to the development of novel algorithms to elucidate previously obscure features and led to an increased reliance on complex workflows to integrate such tools into analyses pipelines. To facilitate the analysis of DNA sequencing data, we created metapipeline-DNA, a highly configurable and extensible pipeline. It encompasses a broad range of processing including raw sequencing read alignment and recalibration, variant calling, quality control and subclonal reconstruction. Metapipeline-DNA also contains configuration options to select and tune analyses while being robust to failures. This standardizes and simplifies the ability to analyze large DNA sequencing in both clinical and research settings. Availability Metapipeline-DNA is an open-source Nextflow pipeline under the GPLv2 license and is freely available at https://github.com/uclahs-cds/metapipeline-DNA.

19 August 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
MLMichael A. Liss
Michael A. Liss
NZNicole Zeltser
Nicole Zeltser
YZYingye Zheng
Yingye Zheng
CLCamden Lopez
Camden Lopez
MLMenghan Liu
Menghan Liu
RLRobin J. Leach
Robin J. Leach
Background: Localized prostate tumors show significant spatial heterogeneity, with regions of high-grade disease adjacent to lower grade disease. Consequently, prostate cancer biopsies are prone to sampling bias, potentially leading to underestimation of tumor grade. To study the clinical, epidemiologic, and molecular hallmarks of this phenomenon, we conducted a prospective study of grade upgrading: differences in detected prostate cancer grade between biopsy and surgery. Methods: We established a prospective, multi-institutional cohort of men with grade group 1 (GG1) prostate cancer on biopsy who underwent radical prostatectomy. Upgrading was defined as detection of GG2+ in the resected tumor. Germline DNA from 192 subjects was subjected to whole-genome sequencing to quantify ancestry, pathogenic variants in DNA damage response genes, and polygenic risk. Results: Of 285 men, 67% upgraded at surgery. PSA density and percent of cancer in pre-prostatectomy positive biopsy cores were significantly associated with upgrading. No assessed genetic risk factor was predictive of upgrading, including polygenic risk scores for prostate cancer diagnosis. Conclusions: In a cohort of patients with low-grade prostate cancer, a majority upgraded at radical prostatectomy. PSA density and percent of cancer in pre-prostatectomy positive biopsy cores portended the presence of higher-grade disease, while germline genetics was not informative in this setting. Patients with low-risk prostate cancer, but elevated PSA density or percent cancer in positive biopsy cores, may benefit from repeat biopsy, additional imaging or other approaches to complement active surveillance. Impact: Further risk stratification of patients with low-risk prostate cancer may provide useful context for active surveillance decision-making.